Pharmaceuticals in the environment: scientific evidence of risks and its regulation
Authors:
Top Cited Papers
- 19 November 2014
- journal article
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 369 (1656) , 20130587
Abstract
During the past two decades scientists, regulatory agencies and the European Commission have acknowledged pharmaceuticals to be an emerging environmental problem. In parallel, a regulatory framework for environmental risk assessment (ERA) of pharmaceutical products has been developed. Since the regulatory guidelines came into force the German Federal Agency (UBA) has been evaluating ERAs for human and veterinary pharmaceutical products before they are marketed. The results show that approximately 10% of pharmaceutical products are of note regarding their potential environmental risk. For human medicinal products, hormones, antibiotics, analgesics, antidepressants and antineoplastics indicated an environmental risk. For veterinary products, hormones, antibiotics and parasiticides were most often discussed as being environmentally relevant. These results are in good correlation with the results within the open scientific literature of prioritization approaches for pharmaceuticals in the environment. UBA results revealed that prospective approaches, such as ERA of pharmaceuticals, play an important role in minimizing problems caused by pharmaceuticals in the environment. However, the regulatory ERA framework could be improved by (i) inclusion of the environment in the risk–benefit analysis for human pharmaceuticals, (ii) improvement of risk management options, (iii) generation of data on existing pharmaceuticals, and (iv) improving the availability of ERA data. In addition, more general and integrative steps of regulation, legislation and research have been developed and are presented in this article. In order to minimize the quantity of pharmaceuticals in the environment these should aim to (i) improve the existing legislation for pharmaceuticals, (ii) prioritize pharmaceuticals in the environment and (iii) improve the availability and collection of pharmaceutical data.Keywords
This publication has 19 references indexed in Scilit:
- Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimationEnvironmental Pollution, 2014
- EU-wide monitoring survey on emerging polar organic contaminants in wastewater treatment plant effluentsWater Research, 2013
- Pharmaceuticals and personal care products (PPCPs): A review on environmental contamination in ChinaEnvironment International, 2013
- Pharmaceutical contaminants of emerging concern in the environmentEnvironmental Toxicology and Chemistry, 2013
- Dilute Concentrations of a Psychiatric Drug Alter Behavior of Fish from Natural PopulationsScience, 2013
- Pharmaceuticals in biota in the aquatic environment: analytical methods and environmental implicationsAnalytical and Bioanalytical Chemistry, 2012
- Human Pharmaceuticals in the Aquatic Environment: A Review of Recent Toxicological Studies and Considerations for Toxicity Testing2012
- Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershedEnvironmental Toxicology and Chemistry, 2009
- A ranking of European veterinary medicines based on environmental risksIntegrated Environmental Assessment and Management, 2008
- Widespread Sexual Disruption in Wild FishEnvironmental Science & Technology, 1998